What is HC Wainwright’s Estimate for NRSN FY2026 Earnings?

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) – Equities research analysts at HC Wainwright upped their FY2026 earnings estimates for NeuroSense Therapeutics in a report issued on Monday, September 28th. HC Wainwright analyst L. Egana-Gorrono now expects that the company will post earnings per share of ($4.45) for the year, up from their previous estimate of ($7.40). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for NeuroSense Therapeutics’ current full-year earnings is ($6.62) per share. HC Wainwright also issued estimates for NeuroSense Therapeutics’ FY2027 earnings at ($7.12) EPS, FY2028 earnings at ($7.58) EPS, FY2029 earnings at ($6.63) EPS and FY2030 earnings at $7.49 EPS.

Separately, Weiss Ratings cut NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $170.00.

NeuroSense Therapeutics Price Performance

Shares of NRSN opened at $4.05 on Wednesday. The company has a market capitalization of $7.70 million, a P/E ratio of -0.37 and a beta of 1.66. NeuroSense Therapeutics has a one year low of $3.83 and a one year high of $26.64. The business’s 50 day simple moving average is $8.21 and its 200-day simple moving average is $12.77.

Hedge Funds Weigh In On NeuroSense Therapeutics

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Yorkville Advisors Global LP acquired a new stake in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 100,000 shares of the company’s stock, valued at approximately $77,000. NeuroSense Therapeutics comprises approximately 0.0% of Yorkville Advisors Global LP’s holdings, making the stock its 24th largest holding. Yorkville Advisors Global LP owned about 0.73% of NeuroSense Therapeutics as of its most recent filing with the SEC. 1.04% of the stock is currently owned by institutional investors.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company is headquartered in Israel and conducts research aimed at addressing biological mechanisms associated with diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurological disorders.

NeuroSense’s leading investigational product is PrimeC, an oral, fixed-dose combination of ciprofloxacin and celecoxib. The therapy is designed to target multiple disease-related pathways, including neuroinflammation and the regulation of RNA processing, and has been evaluated in clinical studies involving patients with ALS.